The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Phase 1

Recruiting

• Conditions: Overweight, Obesity; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

• Registration Number: CTIS2023-508630-34-00
• Lead Sponsor: Eli Lilly & Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-19
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

Must be 45 years old or older, Have BMI of >27.0 kg/m2, Have established ASCVD and/or CKD, With or without T2D as long as HbA1c<10%

Exclusion Criteria

Have Type 1 Diabetes, Have had or plan to have a surgical treatment for obesity, Have an eGFR <20 mL/min/1.73 m2 at screening, Have any of the following cardiovascular conditions = 90 days prior to randomization: Myocardial infarction, Acute coronary syndrome, Stroke, or coronary, peripheral, or carotid artery arterial revascularization procedure, Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2, Have acute decompensated heart failure requiring hospitalization, Have New York Heart Association (NYHA) Classification Class IV heart failure at screening

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified